dr. penson on olaparib monotherapy vs chemo for ovarian cancer
Published 5 years ago • 486 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
1:22
dr. penson on the eligibility criteria for parp inhibitors in advanced ovarian cancer
-
1:30
dr. penson on research with parp inhibitors in ovarian cancer
-
1:25
olaparib in ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
11:22
olaparib in ovarian cancer
-
0:42
dr. penson on re-challenging with parp inhibition in ovarian cancer
-
23:15
is it time to change upfront chemotherapy for ovarian cancer?
-
1:26
dr. penson on biomarkers of response to parp inhibitors in ovarian cancer
-
1:38
dr. liu on cediranib/olaparib in recurrent ovarian cancer
-
1:23
dr. robertson on olaparib for serous ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
0:40
dr. willmott on fda approval of maintenance olaparib in ovarian cancer
-
2:07
maintenance olaparib in patients with ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
2:00
dr. zakashansky on the benefit of maintenance olaparib in brca ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer